Hair Thinning Clinical Trial
Official title:
A Multi-site, Double-blind, Placebo-controlled Clinical Study to Evaluate the Effects of Viviscal Oral Supplements When Used by Females With Self-perceived Thinning Hair
Verified date | November 2014 |
Source | Irish Response t/a Lifes2good |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The purpose of this multi-site, double-blind, placebo-controlled clinical study, conducted
for Lifes2Good, is to evaluate certain physiological effects of Viviscal Oral Supplement
compared to a placebo in female subjects with self-perceived thinning hair associated with
poor diet, stress, hormonal influences, or abnormal menstrual cycles.
Viviscal is an oral food supplement specifically designed to promote the quality of existing
hair growth and/or to promote new hair re-growth for women suffering from temporary thinning
hair. It does not contain hormones, drugs, or industry by-products. Viviscal has been
marketed in Europe for over 15 years. The key ingredient is AminoMar C - a protein rich
compound of marine extracts blended with soluble silica and fortified with Vitamin C.
Viviscal provides essential nutrients to nourish hair naturally from within. Viviscal works
over several months of use to improve the appearance of thinning hair.
Status | Completed |
Enrollment | 96 |
Est. completion date | November 2011 |
Est. primary completion date | November 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 24 Years to 55 Years |
Eligibility |
Inclusion Criteria: 1. Females, ages 21-55 years of age. 2. Clinically-determined general good health as determined by responses to the initial paperwork. 3. Females with self-perceived thinning hair associated with poor diet, stress, hormone influences or abnormal menstrual cycle. 4. Females willing to maintain their normal hair shampooing frequency. 5. Females willing to add the provided oral supplement to their current daily routine. 6. Females willing to not substantially change their current diet, medications, or exercise routines for the duration of the study. If a subject receives physician guidance during the study to change diet, medications, or exercise routine, the subject will need to notify the clinic as soon as possible. 7. Females willing to undergo a brief physical exam to include height, weight, blood pressure, pulse, general physical findings and a scalp exam. The physical exam will occur at Visits 1, 3, and 5. 8. Females willing to have a small dot tattoo applied to the scalp, a small area of hair shaved (approximately 1 cm2) to approximately 1 mm in length, remaining hair in that small area dyed black, and to have photographs performed. If the dot tattoo fades substantially by Visit 3, it may need to be re-inked. 9. Females willing to wash their hair at the testing facility at Visits 2, 4 and 6 with the provided normal shampoo. Subjects may bring their own conditioner to use after shampooing. 10. Individuals with Fitzpatrick I-III photo skin types, (Fitzpatrick IV may be enrolled at the discretion of the clinical investigator). 11. Willingness to maintain a consistent haircut and hair color throughout the 6 month study period. Exclusion Criteria: 1. Females with a known history of intolerance or allergy to fish, seafood or acerola. 2. Individuals with any known allergy or sensitivity to any shampoo/conditioner. 3. Females who are nursing, pregnant, planning to become pregnant during the study. 4. Females who are participating on any clinical research study at Stephens or at another research center or doctor's office. 5. Females who have recently (within the last 6 months) started the use of hormones for birth control or hormone replacement therapy (HRT). Women currently using hormones for birth control or HRT must have been on a stable dose (6 months or longer) in order to be eligible for the study. 6. Females currently using the HairMax light treatment to treat thinning hair. 7. Females who have regularly used Rogaine (Minoxidil) or Nizoral/Ketoconazole within the last 3 months. 8. Females who have used prescription drugs known to affect the hair growth cycle within, 6 months (e.g., hormone-based birth control for less than 6 months). 9. Females suffering from other hair loss disorders, such as alopecia areata, scarring alopecia or androgenetic alopecia. 10. Females who have had hair transplants within 6 months of study start. 11. Individuals with self-reported uncontrolled diseases (i.e. diabetes, hypertension, hyperthyroidism, hypothyroidism, etc. Medical conditions that are under control with or without treatment will be considered on an individual basis by the Investigators. 12. Females with self-reported active hepatitis, immune deficiency, HIV or autoimmune disease. 13. Females having a known active dermatologic condition which, in the opinion of the examining Investigator, might place the subject at a greater risk or interfere with clinical evaluations (e.g., seborrheic dermatitis, psoriasis, atopic dermatitis, advanced skin cancer, etc.) |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
United States | Stephens Associates Inc. | Richardson | Texas |
Lead Sponsor | Collaborator |
---|---|
Irish Response t/a Lifes2good | Stephens & Associates, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hair shedding rate | The numbers of scalp hairs shed at month 3 and month 6 when compared with baseline values. | 6 months | No |
Primary | Hair fiber diameter | Mean vellus hair width change | 6 months | No |
Secondary | Quality of life questionnaires | Quality of life questionnaires relating to perception of quality of hair growth and their wellbeing. | 6 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05019066 -
Oral Herbal Combination Formulation and Hair Growth in Women
|
N/A | |
Completed |
NCT05800496 -
A Clinical Study to Assess the Safety and Effectiveness of Plant Based Biotin in Healthy Human Subjects With Thin, Dry, and Brittle Hair
|
N/A | |
Terminated |
NCT03709563 -
Oral Nutraceutical Supplement With Standardized Botanicals in Males With Self-Perceived Thinning Hair and Loss
|
N/A | |
Recruiting |
NCT06376409 -
Prospective Study of Nutraceutical Supplements to Support Hair Growth in Females
|
N/A | |
Completed |
NCT03206567 -
Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Women With Thinning Hair
|
N/A | |
Recruiting |
NCT06362941 -
Evaluation of an Oral Hair Supplement to Improve Hair Strength and Support Growth in Women and Men
|
N/A | |
Completed |
NCT05332743 -
Nutraceutical Supplement With Vegan Botanicals in Females With Self-Perceived Thinning Hair
|
N/A | |
Recruiting |
NCT04048031 -
Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Peri-menopausal and Menopausal Women With Thinning Hair
|
N/A | |
Completed |
NCT05339958 -
Nutraceutical Supplement With Standardized Botanicals in Males With Thinning Hair
|
N/A | |
Enrolling by invitation |
NCT06174441 -
The Effect of 24-week Dietary Intake of Food Supplements on Hair
|
N/A | |
Recruiting |
NCT06146166 -
The Effects of an Oral Hair Supplement on Hair Density, Growth, and Microbiome
|
N/A | |
Completed |
NCT02302053 -
Efficacy of the New Viviscal Professional Strength Oral Supplement in Females With Thinning Hair
|
N/A | |
Active, not recruiting |
NCT06060834 -
Impact of a Topical Cosmetic Product on Women's Hair
|
N/A | |
Completed |
NCT02297360 -
Viviscal Extra-Strength Formulation To Promote Hair Growth And Decrease Shedding In Women With Thinning Hair
|
N/A | |
Recruiting |
NCT06010745 -
Effectiveness of a Novel Dietary Ingredient on Hair Growth and Skin's Appearance
|
N/A | |
Completed |
NCT04450602 -
A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss
|
N/A | |
Completed |
NCT04450589 -
A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Male Subjects With Hair Loss
|
N/A |